JP3007665B2 - Preventive and therapeutic agent for coronavirus infection and disinfectant - Google Patents

Preventive and therapeutic agent for coronavirus infection and disinfectant

Info

Publication number
JP3007665B2
JP3007665B2 JP2246307A JP24630790A JP3007665B2 JP 3007665 B2 JP3007665 B2 JP 3007665B2 JP 2246307 A JP2246307 A JP 2246307A JP 24630790 A JP24630790 A JP 24630790A JP 3007665 B2 JP3007665 B2 JP 3007665B2
Authority
JP
Japan
Prior art keywords
drug
therapeutic agent
preventive
livestock
crow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2246307A
Other languages
Japanese (ja)
Other versions
JPH04128237A (en
Inventor
淑 古閑
芳博 矢原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nisshin Seifun Group Inc
Original Assignee
Nisshin Seifun Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Seifun Group Inc filed Critical Nisshin Seifun Group Inc
Priority to JP2246307A priority Critical patent/JP3007665B2/en
Publication of JPH04128237A publication Critical patent/JPH04128237A/en
Application granted granted Critical
Publication of JP3007665B2 publication Critical patent/JP3007665B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To obtain the title preventive and therapeutic agent containing a specific galenical drug as active ingredient, without requiring labor, free from problem such as the induction of a virulent virus or the remain of a vaccine in animal when the vaccine is administered. CONSTITUTION:The preventive and therapeutic agent containing a galenical drug (especially preferably Caryophylli Flos, Perillae Herba or Rhei Rhizoma) selected from a group consisting of Caryophylli Flos, Schizonepetae Spica, moxa leaf, Perillae Herba, Rhei Rhizoma, Moutan Cortex, Paeoniae Radix, Houttuyniae Herba, Artemisia capillaris Thus b, Lonicerae Flos, Cinnamoni Cortex, Evodiae Fructus, Ginseng Radix, dindera strychnifolia (Sieb at Zucc.) F.Vill and Prunus mume Sieb at Zucc (Japanese apricot) as active ingredients. When said preventive and therapeutic agent is used to an animal, the form is raw galenical drug, cut material thereof, crush-powdered material or powdered grains or an extract of galenical drug active ingredients or the diluent or the concentrated liquid. The dose expressed in terms of dried galenical drug is 0.001-10g/kg of body weight in the case of oral administration and 0.001mg-1g/ kg in the case of parenteral administration, and the administration is preferably carried out over several days to several ten days.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、家畜類のコロナウィルス感染症の予防およ
び治療剤ならびに消毒薬に関する。詳細には特定の生薬
を含有する家畜類のコロナウィルス感染症の予防および
治療剤ならびにコロナウィルス消毒薬である。
Description: TECHNICAL FIELD The present invention relates to an agent for preventing and treating coronavirus infection in livestock and a disinfectant. In particular, it is a prophylactic and therapeutic agent for coronavirus infection in livestock and a coronavirus disinfectant containing a specific crude drug.

〔従来の技術〕[Conventional technology]

家畜類のコロナウィルス感染症はコロナウィルスの感
染によって起こる疾病で、具体的には、豚伝染性胃腸炎
(TGE)、牛のコロナウィルス感染症、馬のコロナウィ
ルス感染症、犬のコロナウィルス感染症などがある。い
ずれも、激しい下痢を主徴とし、伝染力が強く、家畜の
場合には著しい生産性の低下を招く重大な疾病である。
Coronavirus infection in livestock is a disease caused by coronavirus infection, specifically, infectious gastroenteritis (TGE) in swine, coronavirus infection in cattle, coronavirus infection in horses, and coronavirus infection in dogs. Symptoms. Both are severe diseases, characterized by severe diarrhea, highly contagious and, in the case of livestock, significantly reduced productivity.

かかるコロナウィルス感染症の予防および治療法とし
ては、従来、コロナウィルス感染症に罹患した動物およ
びそれに接触した動物を速やかに隔離すると共に家畜の
場合、畜舎、器物、飼料等による伝染を防止するために
消毒等の必要な処置を行う等の方法、およびTGEの場合
にはワクチンの接種が主として採用されてきたが、手間
のかかるにも拘らず充分満足し得る結果が得られなかっ
た。
As a method for preventing and treating such coronavirus infection, conventionally, animals infected with coronavirus infection and animals in contact therewith are promptly isolated and, in the case of livestock, in order to prevent transmission through livestock houses, vessels, feed, etc. In the case of TGE, vaccination has been mainly employed, although the necessary treatment such as disinfection has been adopted, but satisfactory results have not been obtained despite the laboriousness.

〔発明が解決しようとする課題〕[Problems to be solved by the invention]

従ってかかるコロナウィルス感染症に対して予防およ
び治療効果ならびに消毒効果が高く且つ手間等がかから
ない予防および治療剤ならびに消毒薬についての解明が
求められていたのである。
Therefore, there is a need for elucidation of a prophylactic and therapeutic agent and a disinfectant which have a high preventive and therapeutic effect and a disinfecting effect on such a coronavirus infectious disease and requires little effort.

〔課題を解決するための手段〕[Means for solving the problem]

本発明者等は上記の課題の解決のために鋭意研究の結
果、多数ある生薬のうちの特定のものが、かかるコロナ
ウィルス感染症の予防および治療ならびに消毒に極めて
有効であることを見出して本発明を完成した。
The present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that a specific one of a large number of crude drugs is extremely effective for the prevention and treatment and disinfection of such coronavirus infection. Completed the invention.

すなわち、本発明は、丁字、荊芥、艾葉、蘇葉、大
黄、甘草、牡丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅からなる群から選ばれる生薬の
1種または2種以上を含有する家畜類のコロナウィルス
感染症の予防および治療剤に関する。
That is, the present invention relates to the following: Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu The present invention relates to a preventive and therapeutic agent for coronavirus infectious diseases in livestock, comprising one or more crude drugs selected from the group consisting of ginseng, crow drug and crow plum.

さらに、本発明は、丁字、荊芥、艾葉、蘇葉、大黄、
甘草、牡丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅からなる群から選ばれる生薬の
1種または2種以上を含有する家畜類の飼育箇所および
飼育機具のコロナウィルス消毒薬に関する。
In addition, the present invention provides a sword, a vine, Aiba, soba, rhubarb,
Licorice, Peony, Peony, Jujube, Yin Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu The present invention relates to a coronavirus disinfectant for livestock breeding sites and breeding equipment, which contains one or more crude drugs selected from the group consisting of ginseng, crow drug and crow plum.

丁字、荊芥、艾葉、蘇葉、大黄、甘草、牡丹皮、芍
薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、呉茱 、人参、烏薬および烏梅は、いずれも人間用の生薬とし
て従来から知られているものであるが、かかる生薬が家
畜類のコロナウィルス感染症の予防および治療に有効で
あることはこれまで何ら知られておらず、したがって本
発明はかかる生薬の既知の効能からは全く予想外の発見
に基づくものである。
Chou-ji, Tangaku, Aiba, Soyo, Rhubarb, Licorice, Peony, Shakuyaku, Juyaku, Yin Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, mao, goshu , Ginseng, crow drug and crow plum are all conventionally known as crude drugs for human use, but it has never been shown that such crude drugs are effective in preventing and treating coronavirus infection in livestock. Not known, and thus the present invention is based entirely on unexpected discoveries from the known efficacy of such crude drugs.

以下に、本発明で使用する上記の生薬について簡単に
説明する。
Hereinafter, the crude drug used in the present invention will be briefly described.

丁字(チョウジ)(Caryophylli Flos): 丁字の開花直前のつぼみであり、成分としてオイゲノ
ール、アセチルオイゲノール等を含み、ヒトの健胃薬、
駆虫薬、香辛料、化粧品等として使用されている。
Clove (Caryophylli Flos): A bud just before flowering, containing eugenol, acetyleugenol, etc.
It is used as an anthelmintic, spice, and cosmetics.

荊芥(ケイガイ)(Schizonepetae Spica): 荊芥の花穂であり、成分としてメントン、リモネン等
を含有し、ヒトの鎮痛役、抗炎症薬等として使用されて
いる。
Squizonepetae (Schizonepetae Spica): A spike of scab, containing mentone, limonene, etc. as components and used as an analgesic for humans, an anti-inflammatory drug, and the like.

艾葉(ガイヨウ)(Artemisiae Folium): 艾(ヨモギ)またはやま艾の葉であり、成分としてユ
ーカリプトール、セスキテルペン等を含み、ヒトの止
血、強壮、補血薬等として使用されている。
Artemisiae Folium: It is a leaf of mosaic or mugwort, and contains eucalyptol, sesquiterpene, and the like as components, and is used as a hemostatic, tonic, and blood-supplementing agent for humans.

蘇葉(ソヨウ)(Perillae Herba): 紫蘇の葉であり、成分としてアントシアン色素、リモ
ネン等を含有し、ヒトの鎮静剤、鎮咳剤として、また抗
菌剤として使用されている。
Perillae Herba: Perillae Herba is a leaf of perillae, containing anthocyan dye, limonene and the like as components, and is used as a human sedative, antitussive and antibacterial agent.

大黄(ダイオウ)(Rhei Rhizoma): 大黄および近縁植物の根茎の外層を剥ぎそのまま又は
縦割したものであり、成分としてオキシアントラキノン
誘導体であるクリソファン酸、エモジン、イモジンモノ
エチルエーテル等を含有し、ヒトの健胃苦味薬、緩下
薬、消炎薬等として使用されている。
Rhubarb (Rhei Rhizoma): Rhizoma of rhubarb and closely related plants, the outer layer of the rhizome is peeled off or cut vertically, and contains oxyanthraquinone derivatives such as chrysophonic acid, emodin, imodine monoethyl ether, etc. It has been used as a human stomach bitter medicine, laxative, anti-inflammatory drug and the like.

甘草(カンゾウ)(Glycyrrhizse Radix): 甘草の根であり、成分としてグリチルリチン等を含有
し、ヒトの矯味剤、鎮咳去痰薬等として使用されてい
る。
Licorice (Glycyrrhizse Radix): Glycyrrhizse Radix: It is the root of licorice and contains glycyrrhizin and the like as an ingredient, and is used as a human corrigent, an antitussive expectorant and the like.

牡丹皮(ボタンピ)(Moutan Cortex): 牡丹の根皮であり、成分としてペオノール、安息香酸
等を含有し、ヒトの鎮痛薬、鎮痙薬等として使用されて
いる。
Peony bark (Moutan Cortex): A root bark of a peony, which contains paeonol, benzoic acid, and the like as components and is used as a human analgesic, antispasmodic, and the like.

芍薬(シャクヤク)(Paeoniae Radix): 芍薬の根であり、成分として安息香酸等を含有し、ヒ
トの鎮痛薬等として使用されている。
Paeoniae Radix: The root of a peony, containing benzoic acid and the like as an ingredient and used as a human analgesic.

十薬(ジュウヤク)(Houttuyniae Herba): ドクダミの全草であり、成分としてクエルシトリン、
メチルノニルケトン、カプリン酸等を含有し、ヒトの創
傷、尿道炎に対する抗炎症薬等として使用されている。
Houttuyniae Herba (Houttuyniae Herba): The whole herb of Dokudami, quercitrin,
It contains methyl nonyl ketone, capric acid and the like, and is used as an anti-inflammatory drug for human wounds and urethritis.

蒿(インチンコウ)(Artemisiae Capillaris Spic
a): 茵 蒿はカワラヨモギの花穂であり、成分としてカピラリ
ン、カプラリシン等を含有し、ヒトの消炎、解熱、利尿
薬として使用されている。
Inn Kochin (Artemisiae Capillaris Spic)
a): In Koko is a spikelet of Japanese mugwort and contains capillarin, capraricin, and the like as components, and is used as an anti-inflammatory, antipyretic, and diuretic in humans.

金銀花(キンギンカ)(Lonicerae Flos): スイカズラのつぼみであり、成分としてルテオリンを
含有し、ヒトの浄血、解毒薬として使用されている。
Gold and silver flower (Lonicerae Flos): A bud of honeysuckle, containing luteolin as an ingredient and used as a human blood purification and antidote.

桂皮(ケイヒ)(Cinnamoni Cortex): 桂樹の樹皮であり、成分としてケイヒアルデヒド、酢
酸シンナミル等を含有し、ヒトの解熱、鎮痛、健胃、整
腸薬等として使用されている。
Cinnamoni Cortex (Cinnamoni Cortex): A bark of laurel, containing cinnamaldehyde, cinnamyl acetate, etc. as components, and used as antipyretic, analgesic, stomachic, and intestinal medicine for humans.

杜仲(トチュウ)(Eucommiae Cortex): 杜仲ゴムの樹皮であり、成分としてグッタペルカ等を
含有し、ヒトの強壮薬として使用されている。
Eucommiae Cortex (Eucommiae Cortex): The bark of Eucommiae rubber, containing gutta percha as an ingredient and used as a tonic for humans.

枇杷葉(ビワヨウ)(Eriobotryae Folium): 枇杷の葉であり、成分としてウルソーン、アミグダリ
ン等を含有し、ヒトの健胃薬として使用されている。
Loquat leaf (Eriobotryae Folium): Loquat leaf, containing urthorn, amygdalin, etc. as components and used as a stomachic for humans.

竹茹(チクジョ)(Phyllostachysis Caulis in Taenia
m): ハチクの稈の内層であり、成分としてアルンドイン等
を含有し、ヒトの呼吸器疾患時等に使用されている。
Chikujo (Phyllostachysis Caulis in Taenia)
m): This is the inner layer of the culm of a bee and contains alundin as a component and is used at the time of human respiratory diseases and the like.

麻黄(マオウ)(Ephedrae Herba): 麻黄の地上茎であり、成分としてエフェドリン等を含
有し、ヒトの鎮咳、発汗、利尿薬として使用されてい
る。
Ephedrae Herba: Ephedrae Herba is an above-ground stem of ephedra which contains ephedrine and the like as an ingredient and is used as an antitussive, sweating and diuretic in humans.

大棗(タイソウ)(Zizyphi Fructus): ナツメの果実であり、成分としてオレアノリック酸等
を含有し、ヒトの強壮、利尿薬等として使用されてい
る。
Jujube (Zizyphi Fructus): A fruit of jujube, containing oleanolic acid and the like as an ingredient, and used as a tonic and diuretic for humans.

呉茱 (ゴシュユ)(Evodiae Fructus): ゴシュユの果実であり、成分としてエボダイアミン等
を含有し、ヒトの健胃薬等に使用されている。
Goshu (Goshiyu) (Evodiae Fructus): A fruit of Goshuyu, which contains evodiamine and the like as an ingredient and is used as a stomachic for humans.

人参(ニンジン)(Ginseng Radix): オタネニンジンの根であり、成分としてジンセノサイ
ド等を含有し、ヒトの強壮薬等として使用されている。
Ginseng Radix: Ginseng Radix is a root of ginseng, containing ginsenoside and the like as an ingredient and used as a tonic for humans.

烏薬(ウヤク) ウヤクの根であり成分としてリンデラン等を含有しヒ
トの健胃、鎮痛薬等として使用されている。
Oyaku (Yaku) It is the root of Yaku and contains Linderan as a component and is used as a stomachic and analgesic for humans.

烏梅(ウバイ) ウメの果実を燻製したものであり、成分としてコハク
酸、クエン酸などを含有し、ヒトの清涼性収れん薬、止
瀉、蛔虫駆除薬、解熱薬等として使用されている。
Ume is a smoked plum fruit and contains succinic acid, citric acid, etc. as components, and is used as a refreshing astringent, antidiarrheal, acaricide, and antipyretic for humans.

本発明の予防および治療剤は、家畜類すなわち豚、
牛、馬、山羊、めん羊等の家畜および犬、猫、ネズミ等
のペット動物のコロナウィルス感染症の予防および治療
剤に使用することができ、特に豚、牛、馬、めん羊、
犬、猫等に対して使用した場合には、畜産上、特に養豚
産業上、ペット産業上大きな効果をもたらす。
The preventive and therapeutic agents of the present invention include livestock, that is, pigs,
It can be used as a prophylactic and therapeutic agent for coronavirus infection in domestic animals such as cattle, horses, goats and sheep, and in pet animals such as dogs, cats and rats, especially pigs, cows, horses, sheep,
When used for dogs, cats, etc., it has a great effect on livestock, especially on the pig raising industry and pet industry.

本発明の生薬をコロナウィルス感染症の予防用に使用
した場合には、かかる生薬を投与した家畜類へのコロナ
ウィルスの感染が防止でき、またたとえ感染しても症状
の軽い場合が多い。また、本発明の生薬をコロナウィル
スに感染した家畜類の治療に使用した場合には、生存率
が向上する。
When the crude drug of the present invention is used for prevention of coronavirus infection, it is possible to prevent the infection of livestock to which the crude drug has been administered with coronavirus, and even if the infection occurs, the symptoms are often mild. In addition, when the crude drug of the present invention is used for treatment of livestock infected with coronavirus, the survival rate is improved.

上記した本発明の生薬のうちでも丁字、蘇葉および大
黄がコロナウィルス感染症の予防および治療剤として効
果が高い。
Among the above crude drugs of the present invention, Toji, Soba and Rhubarb are highly effective as agents for preventing and treating coronavirus infection.

本発明の上記生薬を家畜類に投与するにあたっては、
生薬原体のままで、該生薬原体の切断物、粗粉砕物また
は粉粒体の形態で、生薬の活性成分を水やその他の溶媒
で抽出した抽出液の形態で、或は該抽出液を希釈または
濃縮した形態で使用できる。該濃縮形態としては、活性
成分含有抽出液に対して更に濃縮、乾燥、抽出、沈殿等
の濃縮または分離手段を施すことによって活性成分を濃
縮状態(エキス)で含有する液状、半固形状、固形状物
(塊状、粉粒状、顆粒状、錠剤などの成型製剤等)にし
たものがあり、そのいずれもが使用できる。
In administering the crude drug of the present invention to livestock,
The crude drug substance as it is, in the form of a cut, coarsely pulverized or granular material of the crude drug substance, in the form of an extract obtained by extracting the active ingredient of the crude drug with water or another solvent, or the extract Can be used in diluted or concentrated form. As the concentrated form, a liquid, semi-solid, or solid containing the active ingredient in a concentrated state (extract) by subjecting the extract containing the active ingredient to further concentration or separation means such as concentration, drying, extraction, and precipitation. There are shapes (lumps, powders, granules, molded preparations such as tablets, etc.), and any of them can be used.

そして、上記生薬中の活性成分を水やその他の溶媒で
抽出するに際しては、水、その他の溶媒または両者の混
合液中に生薬の原体、その粗粉砕物や粉末を入れ、浸
漬、煎じ等により活性成分を液体中に抽出して行うのが
よい。その際の液温および抽出処理時間は、生薬の種
類、抽出用液体の種類や量、成分の抽出し易さ、熱安定
性、揮発性の有無等の各種の要件に当然依存するが、一
般には、乾燥した生薬原体1gに対して抽出用液体約1〜
1000mlを使用し、約4〜100℃の温度で、約30分〜10日
行うのがよい。抽出処理は、静置下、撹拌下、震盪下の
いずれの状態で行ってもよい。
When extracting the active ingredient in the crude drug with water or another solvent, the crude drug substance, its coarsely pulverized product or powder is placed in water, another solvent or a mixture thereof, and then immersed, decocted, etc. To extract the active ingredient into a liquid. The liquid temperature and extraction processing time at that time naturally depend on various kinds of requirements such as the type of crude drug, the type and amount of the liquid for extraction, ease of extraction of components, thermal stability, and the presence or absence of volatility. Is about 1 g of liquid for extraction per 1 g of dried crude drug substance
It is preferable to use 1000 ml at a temperature of about 4 to 100 ° C. for about 30 minutes to 10 days. The extraction treatment may be performed in any state of standing, stirring, and shaking.

活性成分の抽出に使用できる水以外の他の溶媒の例と
しては、メタノール、エタノール、ブタノール、アセト
ン、酢酸エチル、エーテル、塩化メチレン、クロロホル
ム、ベンゼン、四塩化炭素、石油エーテル等を挙げるこ
とができる。
Examples of other solvents other than water that can be used for extracting the active ingredient include methanol, ethanol, butanol, acetone, ethyl acetate, ether, methylene chloride, chloroform, benzene, carbon tetrachloride, petroleum ether, and the like. .

そのうちでも抽出用液体としては水、メタノール、エ
タノールまたはそれらの混合物が好ましく、特に水が好
ましい。
Among them, the extraction liquid is preferably water, methanol, ethanol or a mixture thereof, and particularly preferably water.

また、上記のようにして調製された活性成分含有抽出
液から活性成分を更にエキスとして濃縮回収する方法と
しては、抽出液の溶媒を加熱下または非加熱下に部分的
にまたは完全に除去する方法、活性成分を沈殿剤等によ
り沈殿分離する方法、活性成分含有抽出液に別の溶媒を
加えてその別の溶媒中に活性成分を移行させて濃縮し必
要に応じて該別の溶媒を除去する方法等が採用できる。
Further, as a method of further concentrating and recovering the active ingredient as an extract from the active ingredient-containing extract prepared as described above, a method of partially or completely removing the solvent of the extract under heating or without heating A method of separating the active ingredient by precipitation with a precipitant, etc., adding another solvent to the active ingredient-containing extract, transferring the active ingredient to the other solvent, concentrating the solution, and removing the other solvent as necessary. A method can be adopted.

生薬に含有されている活性成分の種類、活性成分の抽
出に使用した抽出溶媒の種類等に応じて、濃縮用の該別
の溶媒の種類を選択する必要があるが、通常、低級脂肪
族エーテル、低級ハロゲンアルカン類(クロロホルム、
ジクロロエタン、ジブロモエタン等)、芳香族炭化水素
(ベンゼン、トルエン、キシレン等)、その他の石油系
溶媒(石油エーテル、石油ベンゼン、リグロイン等)が
使用できる。
Depending on the type of active ingredient contained in the crude drug, the type of extraction solvent used for the extraction of the active ingredient, etc., it is necessary to select the type of the other solvent for concentration, but usually lower aliphatic ethers , Lower halogen alkanes (chloroform,
Dichloroethane, dibromoethane, etc.), aromatic hydrocarbons (benzene, toluene, xylene, etc.), and other petroleum solvents (petroleum ether, petroleum benzene, ligroin, etc.) can be used.

活性成分の抽出用および濃縮用に使用する溶媒が、家
畜類の医薬上その含有が禁止されているものである場合
には、本発明の予防および治療剤に最終的に該溶媒が含
まれないように充分精製することが必要である。
When the solvent used for the extraction and concentration of the active ingredient is a substance whose content is prohibited in veterinary medicine, the prophylactic and therapeutic agent of the present invention does not finally contain the solvent. It is necessary to purify sufficiently.

本発明の予防および治療剤を家畜類に投与するにあた
っては、経口投与および非経口投与のいずれもが採用で
きる。経口投与の場合は、上記生薬の原体、該原体の粗
粉砕物や粉末、活性成分含有抽出液、その濃縮エキス等
をそのまま直接家畜類に給与するかまたは飼料や飲料水
と一緒にして給与することにより行う。また、非経口投
与の場合は、注射や塗布等による筋肉内投与、腹腔内投
与、皮下投与、経鼻投与、静脈内投与等のいずれもが採
用できる。非経口投与の場合には活性成分を含有する抽
出液またはその濃縮液の形で使用するのが便利である。
When administering the prophylactic and therapeutic agents of the present invention to livestock, both oral and parenteral administration can be employed. In the case of oral administration, the crude drug substance, a coarsely pulverized product or powder of the drug substance, an active ingredient-containing extract, a concentrated extract thereof, or the like may be directly fed to livestock or together with feed or drinking water. This is done by paying. In the case of parenteral administration, any of intramuscular administration by injection or application, intraperitoneal administration, subcutaneous administration, nasal administration, intravenous administration and the like can be adopted. For parenteral administration, it is convenient to use it in the form of an extract containing the active ingredient or a concentrate thereof.

投与量は、生薬の種類、生薬の投与時の形態(例えば
生薬原体のままか、あるいは活性成分の抽出物か等)、
家畜類の種類や月令、投与形態(経口投与かまたは非経
口投与か)、発病している場合はその症状等により異な
るが、経口投与の場合は、乾燥した生薬原体またはその
粉砕物や粉末に換算して、通常、0.001〜10g/体重kg/日
の範囲で数日〜数十日に亘って投与するのが、また非経
口投与の場合は、乾燥した生薬原体またはその粉砕物や
粉末に換算して、通常、0.01mg〜1g/体重kg/日の範囲で
数日〜数十日に亘って投与するのが好ましい。
The dose is determined by the type of crude drug, the form of the crude drug at the time of administration (for example, whether it is the crude drug substance or an active ingredient extract),
It depends on the type and age of the livestock, the form of administration (whether oral or parenteral) and the symptoms of the disease. In terms of powder, it is usually administered in the range of 0.001 to 10 g / kg of body weight / day for several days to several tens of days, and in the case of parenteral administration, a dried crude drug substance or a crushed product thereof Ordinarily, it is preferably administered in the range of 0.01 mg to 1 g / kg of body weight / day for several days to several tens of days in terms of powder or powder.

更に、本発明の前記生薬は、家畜類に投与するだけで
はなく消毒薬としても使用でき、その場合にはその生薬
の抽出液を希釈して畜舎等の飼育箇所および器物あるい
は飼育に用いる機具に散布するとよい。その際の希釈液
としては、生薬原体に換算して0.00001〜1%w/vの濃度
のものを用いるのがよい。
Furthermore, the crude drug of the present invention can be used not only for domestic animals but also as a disinfectant, in which case the extract of the crude drug is diluted to a breeding place such as a livestock barn or a container or a tool used for breeding. It is good to spray. As the diluent at that time, it is preferable to use a diluent having a concentration of 0.00001 to 1% w / v in terms of a crude drug substance.

以下に本発明を例を挙げて具体的に説明するが、本発
明はそれらの例により限定されない。
Hereinafter, the present invention will be described specifically with reference to examples, but the present invention is not limited to the examples.

実施例 1 ダルベッコ変法MEM培地0.05mlに豚伝染性胃腸炎(TG
E)ウィルス含有液0.05ml(2×103PFU/ml液)(PFU:プ
ラック形成単位)を加え、この液をマイクロプレートに
予め培養した豚腎細胞に接種し、37℃の温度で1時間感
作させ、その後この混合液をとりのぞき1.5%CMC加ダル
ベッコ変法MEM培地を1ml加え37℃で5日間培養した。そ
のときのTGEウィルスのプラック数を数えた(対照例
1)。
Example 1 Porcine infectious gastroenteritis (TG) was added to 0.05 ml of Dulbecco's modified MEM medium.
E) 0.05 ml of virus-containing solution (2 × 10 3 PFU / ml solution) (PFU: plaque forming unit) was added, and this solution was inoculated into porcine kidney cells previously cultured in a microplate and incubated at a temperature of 37 ° C. for 1 hour. After sensitization, the mixed solution was removed, 1 ml of Dulbecco's modified MEM medium supplemented with 1.5% CMC was added, and the mixture was cultured at 37 ° C for 5 days. The number of plaques of the TGE virus at that time was counted (Control Example 1).

別に乾燥した丁字末を5%w/vとなるように蒸留水に
入れ、100℃の温度で30分間ゆっくり加熱して抽出液を
調製した。この抽出液を0.45μmのフィルターで濾過滅
菌し、10倍階段希釈液をそれぞれ調製した。この10倍階
段希釈液の各々0.05mlに上記対照例1で使用したのと同
じTGEウィルス含有液を各々0.05mlを加え、37℃で1時
間感作させ、この液をマイクロプレートに予め培養した
豚腎細胞に接種し、37℃で1時間感作させた。さらにこ
の混合液をとりのぞき1.5%CMC加ダルベッコ変法MEM液
を1ml加え37℃で5日間培養した。そのときのTGEウィル
スのプラック数が上記対照例1の50%以下を示す希釈液
の最大希釈倍率を求めた(実施例1)。
Separately, the dried crest was placed in distilled water at 5% w / v and slowly heated at a temperature of 100 ° C. for 30 minutes to prepare an extract. The extract was sterilized by filtration through a 0.45 μm filter to prepare 10-fold serial dilutions. To 0.05 ml of each of the 10-fold serial dilutions, 0.05 ml of the same TGE virus-containing solution as used in Control Example 1 was added, sensitized at 37 ° C. for 1 hour, and the solution was pre-cultured on a microplate. Pig kidney cells were inoculated and sensitized at 37 ° C. for 1 hour. The mixture was further removed, and 1 ml of Dulbecco's modified MEM containing 1.5% CMC was added. The mixture was cultured at 37 ° C for 5 days. At that time, the maximum dilution ratio of the diluent in which the number of plaques of the TGE virus was 50% or less of the control example 1 was determined (Example 1).

丁字末の代わりに荊芥、艾葉、蘇葉、大黄、甘草、牡
丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲および枇杷葉については5%w/
v、更に竹茹、麻黄と烏薬、烏梅についてはいずれも各
々2.5%w/vずつ合計5%w/v、また大棗、呉茱 、人参については各々1.7%w/vずつ合計5.1%w/vとなる
よう粉末を使用して上記実施例1と同様にしてTGEウィ
ルスのプラック数が上記対照例1の50%以下を示す希釈
液の最大希釈倍率を求めた。
In place of the end of the letter, instead of the end of the sword, Ikuto, Aiba, Soba, Rhubarb, Licorice, Peony, Shakuyaku, Juyaku, Yin 5% w / for hako, gold and silver flowers, cinnamon bark, tochu and loquat leaves
v, Bamboo-boiled, Mao and crow drug, crow plum each, 2.5% w / v each for a total of 5% w / v. As for ginseng, dilution was performed in the same manner as in Example 1 above, except that the number of plaques of the TGE virus was 50% or less than that of Control Example 1 using powder so that the total would be 5.1% w / v by 1.7% w / v each. The maximum dilution of the solution was determined.

上記の結果を下記の第1表に示す。 The above results are shown in Table 1 below.

上記第1表の結果から、丁字、荊芥、艾葉、蘇葉、大
黄、甘草、牡丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅のいずれの場合も、それらの抽
出液を10倍に希釈した場合ですらも、該生薬を含有しな
い対照例1に比べて、TGEウィルスの増殖を50%以下に
抑制し得ることがわかる。更に、この第1表の結果か
ら、丁字、蘇葉、大黄が一番効果があることがわかる。
From the results in Table 1 above, it was found that Toji, Ikuto, Aiba, Sofu, Rhubarb, Licorice, Peony, Shakuyaku, Juyaku, Yin Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu , Ginseng, crow medicament and crow plum, even when their extracts were diluted 10-fold, the growth of TGE virus was suppressed to 50% or less compared to control example 1 containing no crude drug. It can be understood that it can be done. Furthermore, from the results in Table 1, it can be seen that Toji, Soba and Ootake are the most effective.

実施例 2 実施例1で調製した丁字の抽出液を水で100倍に希釈
して牛舎に散布した。この結果、付近の牛舎では牛のコ
ロナウィルス感染症による下痢が発生していたにも拘ら
ず、希釈した丁字抽出液を散布したこの牛舎からは牛の
コロナウィルス感染症の発生が見られなかった。
Example 2 The T-shaped extract prepared in Example 1 was diluted 100-fold with water and sprayed on a barn. As a result, no cattle coronavirus infection was observed in this barn where the diluted T-shape extract was sprayed, despite the occurrence of diarrhea caused by cattle coronavirus infection in the nearby barn. .

実施例 3 蘇葉の粉末0.5重量%と丁字の粉末0.2重量%とを含有
する飼料を種豚(8ヶ月令)に妊娠期間中、及び分娩後
も継続して給与した。この結果、付近の養豚場ではTGE
が発生していたにも拘らず、蘇葉と丁字粉末を給与した
これらの種豚から生まれた子豚にはTGEの発生が見られ
なかった。
Example 3 A feed containing 0.5% by weight of soybean powder and 0.2% by weight of T-shaped powder was fed to a sow (8 months old) during gestation and continuously after parturition. As a result, TGE
Despite this, piglets born from these piglets fed Soba and clove powder did not show any TGE outbreaks.

〔発明の効果〕〔The invention's effect〕

本発明では、丁字、荊芥、艾葉、蘇葉、大黄、甘草、
牡丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅からなる群から選ばれる生薬の
1種または2種以上を含有する家畜類のコロナウィルス
感染症の予防および治療剤とすることによって、手間等
がかからず、しかもワクチンを投与した場合に生じる強
毒性ウィルスの形成や家畜類体内でのワクチンの残留等
の問題を生ずることなくコロナウィルス感染症の予防お
よび治療を極めて効果的に行うことができる。また、本
発明の予防および治療剤は、家畜類の飼育箇所および飼
育機具のコロナウィルス消毒薬としても有用である。
In the present invention, cloves, thorns, Aiba leaves, So leaves, rhubarb, licorice,
Peony, Shakuyaku, Juyaku, Yin Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu A vaccination that does not require much labor by providing a preventive and therapeutic agent for coronavirus infection in livestock containing one or more crude drugs selected from the group consisting of ginseng, crow drug and crow plum Can prevent and treat coronavirus infections very effectively without causing problems such as the formation of highly virulent virus and the residual vaccine in livestock animals. The prophylactic and therapeutic agents of the present invention are also useful as coronavirus disinfectants for livestock breeding sites and breeding equipment.

Claims (2)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】丁字、荊芥、艾葉、蘇葉、大黄、甘草、牡
丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅からなる群から選ばれる生薬の
1種または2種以上を含有する家畜類のコロナウィルス
感染症の予防および治療剤。
[Claim 1] T-shape, twig, Aiba leaf, soba leaf, rhubarb, licorice, peony bark, peony, jujube, ink Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu An agent for preventing and treating coronavirus infection in livestock, comprising one or two or more crude drugs selected from the group consisting of ginseng, crow drug and crow plum.
【請求項2】丁字、荊芥、艾葉、蘇葉、大黄、甘草、牡
丹皮、芍薬、十薬、茵 蒿、金銀花、桂皮、杜仲、枇杷葉、竹茹、麻黄、大棗、
呉茱 、人参、烏薬および烏梅からなる群から選ばれる生薬の
1種または2種以上を含有する家畜類の飼育箇所および
飼育機具のコロナウィルス消毒薬。
(2) T-shape, twigs, Aiba leaves, soybean leaves, rhubarb, licorice, peony, peony, jujube, Kobo, gold and silver flowers, cinnamon bark, eucalypt, loquat leaves, bamboo boiled, maoh, dajutsu,
Goshu A coronavirus disinfectant for livestock breeding sites and breeding tools containing one or more crude drugs selected from the group consisting of ginseng, crow drug and crow plum.
JP2246307A 1990-09-18 1990-09-18 Preventive and therapeutic agent for coronavirus infection and disinfectant Expired - Lifetime JP3007665B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2246307A JP3007665B2 (en) 1990-09-18 1990-09-18 Preventive and therapeutic agent for coronavirus infection and disinfectant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2246307A JP3007665B2 (en) 1990-09-18 1990-09-18 Preventive and therapeutic agent for coronavirus infection and disinfectant

Publications (2)

Publication Number Publication Date
JPH04128237A JPH04128237A (en) 1992-04-28
JP3007665B2 true JP3007665B2 (en) 2000-02-07

Family

ID=17146610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2246307A Expired - Lifetime JP3007665B2 (en) 1990-09-18 1990-09-18 Preventive and therapeutic agent for coronavirus infection and disinfectant

Country Status (1)

Country Link
JP (1) JP3007665B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102408542B1 (en) * 2021-11-29 2022-06-16 농업회사법인 휴림황칠(주) Antibacterial and anti-coronavirus for companion animals, and manufacturing method thereof
KR20240051744A (en) * 2022-10-13 2024-04-22 주식회사 케이씨앤씨 Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient
KR102663613B1 (en) * 2022-10-13 2024-05-16 주식회사 케이씨앤씨 Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
JPH08120255A (en) * 1994-10-25 1996-05-14 T Hasegawa Co Ltd Ultraviolet absorber
KR100346609B1 (en) * 1994-12-28 2002-11-18 주식회사 엘지씨아이 Method for extracting seconoganoside from lonicerae flos
JP3793593B2 (en) * 1995-07-31 2006-07-05 中野 昌俊 Method for producing antiviral agent
US7585523B2 (en) * 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
CA2527989A1 (en) * 2003-06-06 2004-12-16 Johann Wolfgang Goethe University Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)
JPWO2006008802A1 (en) * 2004-07-20 2008-07-31 株式会社栃本天海堂 Herbal medicine for domestic animals
KR100824106B1 (en) * 2006-05-30 2008-04-21 주식회사 씨티씨바이오 Composition and method for treating or preventing white spot syndrome virus
KR100904396B1 (en) * 2007-10-24 2009-06-26 주식회사 알앤엘바이오 Compositon for Increasing Milk Production Containing Artemisia capillaris
JP6156900B2 (en) * 2012-04-06 2017-07-05 智津子 日置 Artemisia extract composition
CN102641474B (en) * 2012-05-03 2014-06-18 青岛绿曼生物工程有限公司 Compound propolis composition for treating chicken mycoplasmosis and preparation method thereof
CN106726494A (en) * 2016-12-22 2017-05-31 云南贝洋生物科技有限公司 A kind of moxaburner
JP2018118959A (en) * 2017-01-20 2018-08-02 養命酒製造株式会社 Antimicrobial composition having lindera umbellate as source material
CN111789880A (en) * 2020-05-07 2020-10-20 郑州航空港百桥生物科技有限公司 Application of cinnamon extract in inhibiting entry and replication of novel COVID-19 coronavirus into cells
KR102526308B1 (en) * 2022-06-23 2023-04-27 한국 한의학 연구원 Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102408542B1 (en) * 2021-11-29 2022-06-16 농업회사법인 휴림황칠(주) Antibacterial and anti-coronavirus for companion animals, and manufacturing method thereof
KR20240051744A (en) * 2022-10-13 2024-04-22 주식회사 케이씨앤씨 Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient
KR102663613B1 (en) * 2022-10-13 2024-05-16 주식회사 케이씨앤씨 Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient

Also Published As

Publication number Publication date
JPH04128237A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
JP3007665B2 (en) Preventive and therapeutic agent for coronavirus infection and disinfectant
JP2599161B2 (en) Preventive and therapeutic agent for Clostridium perfringens infection in livestock and poultry
CN101658551A (en) Honeysuckle composition for resisting virus diseases of pigs
EP2236149A1 (en) Medicinal composition
JP2599159B2 (en) Prevention and treatment of bovine mastitis
CN111481618A (en) Traditional Chinese medicine composition with effects of preventing, treating or assisting in treating African swine fever
WO2020155318A1 (en) Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof
CN102091151A (en) Traditional medicinal composition with wind-dispelling and dampness-removing function and preparation method thereof
WO2022028085A1 (en) Spray for treating cervical spondylosis and preparation method therefor
JP2535559B2 (en) Agent for the prevention and treatment of pruritus in fish
CN105982995A (en) Specific traditional Chinese veterinary oral medicine for treating chronic hog cholera
CN105168807A (en) Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and preparation method thereof
CN114470042B (en) Composition for preventing and treating liver injury of animals as well as preparation method and application thereof
CN106421486A (en) Veterinary traditional Chinese medicine composition with heat clearing and toxicity removing effects and preparation method thereof
JP2535555B2 (en) Agent for preventing and treating streptococcal disease in fish
JP2599160B2 (en) Preventive and therapeutic agent for staphylococcal disease in chickens
JP2701930B2 (en) Prevention and treatment of pseudorabies in animals
CN110721256B (en) Traditional Chinese medicine composition for preventing and treating teniasis of laying hens and preparation method thereof
CN103405504A (en) Traditional Chinese medicine granules for treating respiratory bovine infectious rhinotracheitis and preparation method thereof
CN102380038A (en) Medicine for treating scrofula and red-hot needle therapy
CN107233454B (en) Traditional Chinese medicine and Tibetan medicine composition for preventing and treating livestock diarrhea
CN100400073C (en) Chinese medicine Guiling prepn for treating women's disease and dermatosis and its production process
CN115671192B (en) Traditional Chinese medicine composition for preventing and treating taeniasis of ducks
CN113181317B (en) Traditional Chinese medicine composition, preparation method thereof and application thereof in preventing diarrhea or resisting diarrhea
JP2821211B2 (en) Prophylactic and therapeutic agent for Klebsiella pneumoniae infection

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071126

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081126

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091126

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091126

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101126

Year of fee payment: 11

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101126

Year of fee payment: 11